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Background: Asthma is considered a global public health issue requiring a significant medical expenditure as a
result of its high prevalence and the low rate of disease control.
Objective: This is the first nationwide survey of severe asthma patients carried out in Israel. In this study we aimed
to assess health resources utilization, compliance with treatment and disease-control in a subgroup of patients
with severe asthma in Israel.
Material and method: One hundred and twenty-three patients with a diagnosis of asthma for more then one
year, as well as a hospitalization during the last 12 months due to asthma exacerbation or maintenance systemic
steroids therapy, were included in this non-interventional observational study.
Results: Asthma was uncontrolled in 43.9%, partly controlled in 50.4% and well controlled in only 5.7%. The majority
of the patients (83%) were compliant with drug treatment.
Conclusion: The fact that 83% of the asthma patients included in this study were compliant with their asthma
therapy was not manifested in asthma control. Therefore concrete tools are required for achieving and maintaining
asthma control, especially in the treatment of the most severe asthmatic patients.
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GuidelinesIntroduction
Asthma represents a major public health concern, with
increasing incidence and prevalence worldwide [1].
Asthma affects over 300 million people all over the
world and is one of the most common chronic diseases
[2,3]. Estimates of the prevalence of asthma range from
7% in France and Germany, to 11% in the USA and 15-
18% in the United Kingdom [2]. Approximately 20% of
these patients have severe asthma, of which 20% are
inadequately controlled [4]), and these patients are at
particularly high risk of exacerbation, hospitalization
and demise often suffering from a radically impaired
quality of life. The medical expenditure related to asthma
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reproduction in any medium, provided the orincreasing healthcare costs has raised this disease to high
priority in terms of finding new therapeutic as well as
improved compliance modalities.
Various studies indicate that the burden of illness is
not necessarily associated with asthma itself but with the
lack of asthma control [5]. The unfavorable effects of in-
adequate asthma control range from increased risk of ex-
acerbation and emergency visits, to hospitalization and
death [6,7].
The aim of this survey was to assess health resources
utilization, compliance with treatment and disease-control
in a subgroup of patients with severe asthma in Israel.
Material and methods
Study population and procedures
This is a non-interventional observational study based
on a single patient visit conducted in 12 Israeli centers
by pulmonologists, all members of the Israeli Pulmonary
Society. The patients completed Hebrew-translated
standard, international used questionnaires regarding
asthma control, therapy compliance and quality of life,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographics – Socio-economic and medical
history
Total Number of recruited patients 123
*Age median (range) 52 (19-87)
Married 80 (65%)
Completed high school 76 (62%)
Employed 36 (29%)
Living in urban areas 97 (79%)
Hypertension 38 (31%)
Diabetes Mellitus 22 (18%)
All the results are presented as: n (% of the total).
*Age is expressed as median (range).
Table 2 Asthma related information
Diagnosis of asthma below the age of 40 93 (75.6%)
Allergic rhinitis 68 (55%)
Food or drug allergy 24 (19.5%)
Atopic dermatitis 16 (13%)




#Positive Skin test/RAST 32/46 (69.5%)
All the results are presented as: n (% of the total).
*FEV1 and PEF are expressed as percent of predicted (n=119).
# Skin test/RAST was available only in 46 patients.
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regard to severity, disease-control, comorbidities and
treatment. More specifically, questionnaires were divided
into five parts: 1) demographics 2) health resource
utilization 3) compliance to treatment based on the
standard Asthma Compliance Test [8], 4) level of
asthma-control based on the standard Asthma Control
Test [9]) and 5) asthma history and treatment. The first
3 parts were completed by the patients and the last 2
parts by the physicians. Patient's questionnaires were
self-administered and completed in the out-patient clinic
waiting area while physicians completed their question-
naires just after the patient's visit.
Patients above the age of 18 were included in this study
after signing informed consent. Inclusion criteria were a
diagnosis of asthma (based on the ATS and GINA guide-
lines) for more then one year together with either a
hospitalization during the last 12 months due to asthma
exacerbation, or maintenance systemic steroids therapy for
at least 50% of the year. Total IgE level from up to
12 months before visit 1 until one month after visit 1 was
obtained. All patients fulfilling inclusion criteria were
asked to participate in this survey, during a 12 month
period of time. Asthmatic patients who were hospitalized
for reasons other than asthma, or patients with a diagnosis
of COPD, were excluded from this survey. Asthma-control
was assessed for every patient according to the Global Ini-
tiative for Asthma (GINA) update of 2006 [10,11].
Ethical considerations
This observational survey was performed according to
the principles of Good Clinical Practice, the Helsinki
Declaration, and national laws and regulations for clin-
ical studies. This survey received extraordinary approval
from the Israeli Ministry of Health which authorized the
participation of all affiliated pulmonologists in this study
based upon the approval of the Independent Ethics
Committee of Kaplan Medical Center (Rehovot) and re-
ceipt of the patients’ written informed consent.
Results
Demographics, socio-economic and medical history
Results are presented in Table 1. One hundred and twenty-
three patients were included in this survey during
12 months. One hundred and twelve (91.1%) were Jews.
Seventy one percent of the participants were un-employed
(n=87); 84.8% of the un-employed were either retired (44%
of them) or unable to work for health reasons (46% of
them). Twenty-four percent had pets at home, of which
72.4% were dogs.
Asthma-related information
Asthma-related information is presented in Table 2. IgE
levels were available in 101 patients, the median levelwas 200 Units/ml. Only 3 patients were current smokers
(2.4%). The median number of exacerbations, hospitaliza-
tions in the intensive care unit and intubation episodes
was also recorded (Table 3). According to the Global
Initiative for Asthma (GINA) classification [11], asthma
was partly controlled in 50.4% of the patients, uncon-
trolled in 43.9%, and well controlled in only 5.7%.
Treatment
Ninety percent of the patients were treated with short-
acting beta-2-agonists (mostly salbutamol/albuterol), 19.2%
with long-acting beta-2-agonists (LABA) (formoterol pre-
ferred among other LABA), 15% inhaled corticosteroids
(budesonide preferred), and 83.7% inhaled combination
therapy (salmeterol/fluticasone preferred). Other drugs
included montelukast (n = 37, 30%), theophylline (n = 29,
23.6%), and omalizumab (n= 26, 21.1%). No patient
received LABA alone. The majority (68%) of the patients
receiving LABA did so on-top of inhaled combination
therapy while the rest (32%) were treated with separate
LABA and inhaled corticosteroids. Amongst patients
treated with inhaled combination therapy 87% received
the maximal dose (salmeterol/fluticasone 500 mcg
two times per day or formoterol/budesonide 320mcg
two times per day and only 13% received a smaller dose
(salmeterol/fluticasone 250 mcg two times per day or
Table 3 Exacerbations, Hospitalizations & Intubation
Median number of exacerbations within the last
12 month (0-25)
4
Median number of exacerbations over the past
5 years (0-100)
5/year
History of hospitalization in ICU and intubation 17.0%
Table 5 Compliance and asthma-control
Use steroids daily 43.0%
Afraid/very afraid of side effects 51.2%
Stated they were always compliant with treatment 83.0%
Aware of the need for continuous treatment 92.6%
Thought lack of compliance would have a negative
impact on their disease
95.0%
Thought treatment with tablets was more efficient
than inhalation.
39.0%
Denied the last statement 17.4%
Stated asthma was partially or not-at-all controlled 49.0%
Stated asthma was well controlled 8.3%
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three percent received corticosteroids systemically (pred-
nisone preferred) as a maintenance therapy. The most
common treatment-associated adverse events included
osteoporosis, obesity, and hypertension.
Quality of life and compliance
Visits to the emergency room, number of hospitaliza-
tions and the average hospital-stay is shown in Table 4.
Information about compliance and asthma-control is
shown in Table 5. More than half of the patients
refrained from continuous steroid use out of fear of side
effects. The majority of the patients (83%) declared full
compliance with their prescribed medications and 92.6%
were fully aware of the need for continuous preventive
treatment. Sixty-five percent of the patients declared that
asthma restricted their activities frequently or perman-
ently. Forty-nine percent of all 123 patients stated that
their asthma was not at all, or only partially, controlled,
whereas only 8.3% thought it was well controlled. Forty-
three percent of the patients did not answer this ques-
tion. In the subgroup of patients treated with systemic
corticosteroids (n = 53) and also amongst patients which
received omalizumab (n = 26) there was a trend to better
asthma control which did not however reach statistical
significance.
Discussion
This is the first nationwide survey undertaken in Israel
concerning severe asthma patients. In this study we found
that the majority of the patients (83%) were compliant
with drug treatment. However this high self-declared com-
pliance did not translate into asthma control. According to
2006 GINA assessment, 94.3% of patients had partially-
controlled or uncontrolled asthma in this study. The me-
dian number of exacerbations within the last year wasTable 4 Quality of Life: results expressed as median
(range) or percentage of total
Visits to the ER 2 (0-24)
Hospitalizations within last 12 months 1 (0-20)
Hospitalizations in last 5 years 5 (0-60)
Duration of hospital stay 4 (1-25)
Working days lost due to asthma 15 (0-365)
Asthma attacks daily 65.0%
Woke up 4 or more times a night per week 48.8%four. The results of this survey are based on questionnaires
filled in by patients and physicians, and differ somewhat
from the results of the telephone survey performed by
Chapman et al. [7] in Canada, although both surveys con-
firmed the high prevalence of uncontrolled asthma. Forty-
nine percent of all 123 patients stated that their asthma
was not at all or only partially controlled. Forty-three per-
cent of the patients did not answer this question, but tak-
ing into account other answers (i.e., 65% of patients stated
they had daily asthma attacks) we can evaluate that the
percentage of patients with partially or non-controlled
asthma is very high. This assumption is also based on the
fact that only 8.3% of the patients thought that their
asthma was fully controlled. The pulmonologists found
that only 5.7% of the patients had well-controlled asthma,
which is quite consistent with the patients’ self-evaluation
of well-controlled disease. In the Reality of Asthma Con-
trol (TRAC) study [12] 53% of adults who reported having
asthma were uncontrolled. In the INSPIRE study [13] 51%
of the patients had uncontrolled asthma, as assessed by
the Asthma Control Questionnaire. Although study popu-
lations and methodology are very different in these two
studies the percentage of uncontrolled asthma is quite
similar. In 2009 Demoly et al. published a cross-sectional
study of 37,476 adults in France, Germany, Italy, Spain
and the UK in which 50.4% of asthma patients reported
having partially-controlled disease [2]. Severe persistent
asthma causes a substantial morbidity and mortality bur-
den and is frequently inadequately controlled despite in-
tensive guideline-based therapy. The high percentage of
patients with asthma under little or no control in our
study is partially due to the extremely restrictive inclusion
criteria of our survey. Nevertheless, according to GINA
guidelines, asthma control can be achieved and maintained
amongst the majority of asthmatics. In our study, although
83.7% of the patients used combination therapy (inhaled
steroids and LABA) only 30% used montelukast and
21% omalizumab, despite the severity and poor control-
level of their disease. Although there was a trend
amongst better asthma control in the subgroup of patients
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this difference did not reached statistically significance as
compared with the total population. As many as 83% of
the patients reported constant compliance with their pre-
scribed treatment. We had no possibility to reconcile the
patient's reports concerning the high compliance to treat-
ment, with prescriptions refills or other more objective
measure. There are more objective methods to assess
compliance with treatment but as this was a non-inter-
ventional, observational survey, we were limited to the
use of questionnaires only. Although this information is
based on patients report only, authors believe that there
is room for improvement of current treatment regimens
in the subset of patients presented in this study.
The limitations of this survey are firstly the small size
of the study group. The relatively small size of the
group can be explained by the restrictive inclusion cri-
teria. It is not a general survey of asthma control in Is-
rael but a survey of a severe asthmatic population.
Moreover, as participation to this national survey was
on a volunteer basis, not all the hospitals and pulmo-
nologists, took an active part in this survey. Neverthe-
less we do think that this is a representative sample of
the sub-population of patients with severe asthma. It
should also be stressed that since there is no uniform
definition of severe asthma, the results of this study are
limited to the recruited population and not to all severe
asthmatics. Secondly, we did not analyze the association
of asthma control with other diseases, health attitudes
(obesity, smoking,) or treatments. The third limitation
is the use of the questionnaire to assess compliance with
asthma medication. The patients' questionnaires were
self-administered and completed. There are more object-
ive methods to assess compliance but as this was a non-
interventional survey we used validated questionnaires.
Finally it might be argued that surveying patients in hos-
pital facilities would be biased towards including mostly
uncontrolled asthma patients since such patients are
more likely to require care in a hospital setting.
Conclusions
In this survey, asthma impairedqualityof life andwas amajor
causeof hospitalizations, emergency roomvisits andabsence
from work/school. Although most patients surveyed in this
study (83%) declared full treatment compliance, this over-
whelming number did not translate into satisfactory disease
control, as only 5.7 - 8.3% of the patients (physicians’ versus
patients’ evaluation), claimedwell controlled asthma. Several
studies, including this survey, show that the illness burden is
not only associatedwith the severity of thediseasebutmostly
with the lack of asthma control. More concerted efforts in
achieving and maintaining control are needed. Other treat-
ment options for severe asthmatic patients shouldbe consid-
eredsincemostoftheseverepatientswerenotwellcontrolled.Appendix 1
List of centers participating in this trial who recruited
more then 5 patients, Name of PI (and number of
patients they recruited).
 Kaplan Medical Center, Rehovot, Dr. G. Fink, (30).
 Shaare Zedek Medical Center, Jerusalem, Dr. G.
Izbicki (15)
 Barzilai Medical Center, Ashkelon, Dr. Z. Weiler (11)
 Macabi and Meuhedet Sick funds, Jerusalem, Dr. A.
Grossman (11)
 Sheba Medical Center, Tel-Hashomer, Prof. Y. Ben-
Dov (10)
 Hadassah Medical Center, Jerusalem, Prof. R. Breuer
(10)
 Assaf Harofeh Medical Center, Zrifin, Dr. D. Stav (8)
 Hillel Yaffe Medical Center, Hadera, Dr. M.
Bekerman (7)
 Haemek Medical Center, Afula, Dr. M. Yunis (7)
 Poria Medical Center, Tiberias, Dr. C. Sismolo (5)
 Three other centers recruited a total of nine
patients together.
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